Posted: 7 June 2023
Transformative cancer diagnostics technology company Rhythm Biosciences Ltd (ASX: RHY) (Rhythm or the Company) is pleased to announce that the abstract detailing the main results from the clinical trial for ColoSTAT®, its simple blood test for the detection of colorectal cancer (CRC), was published as part of the 2023 ASCO (American Society of Clinical Oncology) Annual Meeting.
The poster presentation associated with the abstract (attached to this announcement) was presented by Dr. Trevor Lockett, as part of the session taking place on 5 June 2023, 8am-11am (US CDT). (See ASX announcement 6 April 2023).
The multi-centre clinical study detailed in the abstract was designed to evaluate the performance of ColoSTAT® in detecting CRC compared to colonoscopy. The study involved two cohorts: those recently diagnosed with CRC using colonoscopy and proceeding to surgery or neoadjuvant treatment, and those with no CRC history scheduled for colonoscopy.
The clinical trial successfully achieved its primary endpoint, with ColoSTAT® demonstrating a sensitivity of 81% and specificity of 91% in detecting CRC. Furthermore, the study’s exploratory endpoint found that ColoSTAT® demonstrated consistent sensitivity across different stages of the disease.
The abstract is available on the Rhythm Biosciences website at: https://rhythmbio.com/publications_and_posters
Globally an estimated 2 million people are diagnosed with CRC each year, and almost 1 million lives were lost to the disease in 2020. It is predicted that the global number of CRC cases will reach 3.2 million in the next 20 years. The challenge with CRC globally has been low participation in screening programs and the increasing incidence rates, particularly among the younger people. It has been shown that 11% of people diagnosed with CRC are below the age of 50, posing a tremendous public health challenge, premature death and increased healthcare costs.1
Rhythm Chief Commercial Officer Ms. Elena Deak commented: “Our presentation at ASCO has given us the opportunity to inform the medical community about ColoSTAT and its simple methodology for the detection of CRC. We are committed to improving the screening participation rate of Colorectal Cancer, with our simple blood test ColoSTAT®.”
